Global pharma major Lupin Ltd, May 06th, announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Iloperidone Tablets to market a generic equivalent of Fanapt® Tablets of Vanda Pharmaceuticals Inc., and also Pregabalin Capsules.
The products will be manufactured at Lupin’s facility in Goa and Aurangabad, India.
Pregabalin Capsules (RLD Lyrica®) had estimated annual sales of USD 263 million in the U.S. (IQVIA MAT March 2022).
Share price of Lupin gained 0.56 per cent to Rs 728.0 at 11:28AM (IST) in Monday’s trade. The scrip hit a high of Rs 730.0 and low of Rs 713.65 so far during the session. The stock had closed at Rs 723.95 in the previous session, reports the portal TheEconomicTimes.